公开(公告)号：US20200261476A1

公开(公告)日：2020-08-20

申请号：US16067906

申请日：2017-01-05

Applicant: KEIO UNIVERSITY ,  TOKYO INSTITUTE OF TECHNOLOGY

Inventor： Hideyuki SAYA ,  Osamu NAGANO ,  Kenji TSUCHIHASHI ,  Kentaro SUINA ,  Nobuhiro NISHIYAMA ,  Hiroyasu TAKEMOTO ,  Takahiro NOMOTO ,  Makoto MATSUI ,  Keishiro TOMODA ,  Naoki YAMADA ,  Tsukasa NISHIMORI

IPC: A61K31/635 ,  A61K47/60

Abstract: The present invention is directed to provide antitumor agent including water-soluble sulfasalazine as an active ingredient. Antitumor agents were obtained with, as the water-soluble sulfasalazine, a PEG-modified sulfasalazine represented by the following formula: wherein an average value of n is 4 or larger and 1136 or smaller.

公开(公告)号：US20220347125A1

公开(公告)日：2022-11-03

申请号：US17610243

申请日：2020-05-07

Applicant: Keio University

Inventor： Hideyuki SAYA ,  Osamu NAGANO ,  Yuji OTSUKI

IPC: A61K31/137 ,  A61K31/655 ,  A61K31/198 ,  A61P35/00 ,  G01N33/50

Abstract: [Problem] To provide novel anti-tumor agents and combination drugs.
[Means to solve] To provide an anti-tumor agent containing, as an active ingredient, a glutathione level reducer or a glutathione S-transferase inhibitor, the anti-tumor agent being adapted to be administered simultaneously with an effective amount of a compound (II); an anti-tumor agent including a compound (II) as an active ingredient, the anti-tumor agent being adapted to be administered simultaneously with an effective amount of a glutathione level reducer or a glutathione S-transferase inhibitor; or an anti-tumor agent containing, as active ingredients, a compound (II) and a glutathione level reducer or a glutathione S-transferase inhibitor, where R5 is a linear or branched C1-6 alkyl group, R6 is hydrogen or halogen, R7 is a linear or branched C1-6 alkyl group optionally substituted with a substituent, the substituent being hydroxy or phenyl, and R8 is hydrogen or halogen.

公开(公告)号：US20170105984A1

公开(公告)日：2017-04-20

申请号：US15113932

申请日：2015-01-23

Applicant: KEIO UNIVERSITY

Inventor： Hideyuki SAYA ,  Osamu NAGANO ,  Shogo OKAZAKI

IPC: A61K31/454 ,  A61K31/655 ,  A61K45/06

CPC classification number: A61K31/454 ,  A61K31/655 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention is directed to provide cancer stem cell proliferation inhibitors and inducers of intracellular accumulation of reactive oxygen species. To this end, provided are cancer stem cell proliferation inhibitors and inducers of intracellular accumulation of reactive oxygen species in a cancer stem cell each containing pimozide or sertindole as an active ingredient.

公开(公告)号：US20200017834A1

公开(公告)日：2020-01-16

申请号：US16490786

申请日：2018-03-07

Applicant: KEIO UNIVERSITY

Inventor： Hideyuki SAYA ,  Yoshimi ARIMA ,  Takashi SEMBA ,  Akiyoshi KASUGA

IPC: C12N5/071 ,  C12Q1/02 ,  A61K49/00 ,  C12N5/095 ,  A01K67/027

Abstract: Provided is an epithelial tissue stem cell derived from an adult, which lacks at least one tumor suppressor gene.

公开(公告)号：US20230348573A1

公开(公告)日：2023-11-02

申请号：US18027999

申请日：2021-09-24

Applicant: KEIO UNIVERSITY ,  JAPAN as represented by DIRECTOR GENERAL of NATIONAL INSTITUTE OF INFECTIOUS DISEASES ,  RIKEN ,  SHIGA UNIVERSITY OF MEDICAL SCIENCE ,  THE UNIVERSITY OF TOKYO

Inventor： Masaru TAKESHITA ,  Tsutomu TAKEUCHI ,  Katsuya SUZUKI ,  Hideyuki SAYA ,  Yoshimasa TAKAHASHI ,  Saya MORIYAMA ,  Hidehiro FUKUYAMA ,  Chieko OKAMURA ,  Mikako SHIROUZU ,  Takehisa MATSUMOTO ,  Katsuhiko KAMADA ,  Yasushi ITOH ,  Hirohito ISHIGAKI ,  Misako NAKAYAMA ,  Yoshinori KITAGAWA ,  Yoshihiro KAWAOKA

IPC: C07K16/10 ,  A61P31/14

CPC classification number: C07K16/1003 ,  A61P31/14 ,  C07K2317/565

Abstract: An antibody against spike protein of SARS-CoV-2 is provided, the antibody having a specific heavy chain variable region and a specific light chain variable region, or a fragment of the antibody, the antibody or fragment thereof inhibiting the binding between the spike protein of SARS-CoV-2 and ACE2, the antibody or fragment thereof inhibiting SARS-CoV-2 infection; and a pharmaceutical composition including the antibody or fragment thereof and a pharmaceutically acceptable carrier, the pharmaceutical composition including two or more kinds of the antibody or fragment thereof.

公开(公告)号：US20200316027A1

公开(公告)日：2020-10-08

申请号：US16753209

申请日：2018-10-02

Applicant: KEIO UNIVERSITY

Inventor： Hideyuki SAYA ,  Oltea SAMPETREAN ,  Naoyoshi KOIKE ,  Nobuo KUBOTA

IPC: A61K31/4168

Abstract: The object of the present invention is to provide a novel pharmaceutical for suppressing cancer stem cells. In the present invention, a mitochondria inhibitor comprising a 2-nitroimidazole derivative is applied to the cancer stem cell as an active ingredient.